Aquestive Therapeutics Inc’s filing revealed that its Chief Innovation/Tech Officer Schobel Alexander Mark unloaded Company’s shares for reported $0.3 million on Mar 15 ’24. In the deal valued at $6.00 per share,50,000 shares were sold. As a result of this transaction, Schobel Alexander Mark now holds 984,476 shares worth roughly $4.01 million.
Then, Schobel Alexander Mark sold 25,000 shares, generating $129,685 in total proceeds. Upon selling the shares at $5.19, the Chief Innovation/Tech Officer now owns 1,040,371 shares.
Raymond James initiated its Aquestive Therapeutics Inc [AQST] rating to an Outperform in a research note published on March 28, 2024; the price target was $7. H.C. Wainwright began covering AQST with “Buy” recommendation on April 22, 2019. Lake Street started covering the stock on January 03, 2019. It rated AQST as “a Buy”.
Price Performance Review of AQST
On Monday, Aquestive Therapeutics Inc [NASDAQ:AQST] saw its stock fall -0.73% to $4.07. Over the last five days, the stock has lost -1.45%. Aquestive Therapeutics Inc shares have risen nearly 101.49% since the year began. Nevertheless, the stocks have risen 263.39% over the past one year. While a 52-week high of $6.23 was reached on 03/18/24, a 52-week low of $1.09 was recorded on 01/02/24. SMA at 50 days reached $3.73, while 200 days put it at $2.30. A total of 1.37 million shares were traded, compared to the trading of 4.07 million shares in the previous session.
Levels Of Support And Resistance For AQST Stock
The 24-hour chart illustrates a support level at 3.97, which if violated will result in even more drops to 3.87. On the upside, there is a resistance level at 4.16. A further resistance level may holdings at 4.25. The Relative Strength Index (RSI) on the 14-day chart is 47.14, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.19, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 90.12%. Stochastics %K at 9.88% indicates the stock is a buying.
How much short interest is there in Aquestive Therapeutics Inc?
A steep rise in short interest was recorded in Aquestive Therapeutics Inc stocks on Mar 15, 2024, growing by 0.33 million shares to a total of 2.32 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 1.99 million shares. There was a rise of 14.22%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 3.97% of the overall stock float, the days-to-cover ratio (short ratio) rose to 0.7.
The most recent change occurred on August 20, 2018 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $23 price target.
